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Abstract
Background: We previously reported that in pathogenic mismatch repair (path_MMR) variant carriers, the incidence
of colorectal cancer (CRC) was not reduced when colonoscopy was undertaken more frequently than once every 3
years, and that CRC stage and interval since last colonoscopy were not correlated.
Methods: The Prospective Lynch Syndrome Database (PLSD) that records outcomes of surveillance was examined
to determine survival after colon cancer in relation to the time since previous colonoscopy and pathological stage.
Only path_MMR variants scored by the InSiGHT variant database as class 4 or 5 (clinically actionable) were included
in the analysis.
Results: Ninety-nine path_MMR carriers had no cancer prior to or at first colonoscopy, but subsequently developed
colon cancer. Among these, 96 were 65 years of age or younger at diagnosis, and included 77 path_MLH1, 17 path_
MSH2, and 2 path_MSH6 carriers. The number of cancers detected within < 1.5, 1.5–2.5, 2.5–3.5 and at > 3.5 years after
previous colonoscopy were 9, 43, 31 and 13, respectively. Of these, 2, 8, 4 and 3 were stage III, respectively, and only one
stage IV (interval 2.5–3.5 years) disease. Ten-year crude survival after colon cancer were 93, 94 and 82% for stage I, II and III
disease, respectively (p < 0.001). Ten-year crude survival when the last colonoscopy had been < 1.5, 1.5–2.5,
2.5–3.5 or > 3.5 years before diagnosis, was 89, 90, 90 and 92%, respectively (p = 0.91).
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Conclusions: In path_MLH1 and path_MSH2 carriers, more advanced colon cancer stage was associated with
poorer survival, whereas time since previous colonoscopy was not. Although the numbers are limited,
together with our previously reported findings, these results may be in conflict with the view that follow-up
of path_MMR variant carriers with colonoscopy intervals of less than 3 years provides significant benefit.
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Background
Initially, colonoscopy every third year was advocated to
prevent death from colorectal cancer (CRC) in Lynch
Syndrome (LS), whereas more recent clinical guidelines
suggest colonoscopy at least once every 2 years, begin-
ning between 20 and 25 years of age [1]. However, we
have recently reported that for pathogenic mismatch re-
pair (path_MMR) variant carriers, 1–2 yearly colonos-
copy surveillance strategies do not result in a lower
incidence of CRC, compared to a three-yearly strategy
[2]. Recently, the Prospective Lynch Syndrome Database
(PLSD) reported CRC stage data from 9 countries show-
ing that 1–2 yearly colonoscopy was not associated with
a diagnosis of CRC at an earlier stage than 3-yearly col-
onoscopy [2]. These findings were consistent with a re-
port of no difference in CRC incidence and stage in LS
patients between Germany (where colonoscopy surveil-
lance is performed yearly), the Netherlands (1–2 yearly)
or Finland (2–3 yearly) [3].
Geography and differences in follow-up practices
might impact cancer risks, although no significant differ-
ences were identified in the most recently updated series
of the PLSD study, which included 6350 path_MMR car-
riers who were prospectively observed for 51,646 follow-
up years [4]. A recent single centre and retrospective
French study suggested that an optimized colonoscopic
surveillance program in LS patients might improve
screening quality and possibly decrease CRC occurrence,
but long-term prospective studies are needed to confirm
these findings [5].
Because the current prospective evidence suggests that
annual colonoscopies compared to three yearly colonos-
copies do not benefit path_MMR carriers in terms of
CRC incidence or earlier cancer stage at diagnosis, we
aimed to determine if survival after colon cancer differs
according to the intervals of colonoscopies undertaken
prior to cancer diagnosis in path_MMR carriers. We also
examined the relationship between stage at diagnosis
and survival.
Methods
PLSD design
PLSD is an international, multi-centre database record-
ing prospective observational data on path_MMR car-
riers under surveillance by colonoscopy [2, 6–10]. All
collaborating centres undertook genetic testing with ap-
propriate informed consents according to local and na-
tional requirements. No named data were exported to
the PLSD.
Inclusion criteria and statistical analysis
Inclusion criteria comprised only carriers with variants
scored by the InSiGHT variant database (https://www.
insight-group.org/variants/databases/) as class 4 and 5
(clinically actionable), and having a colon cancer de-
tected during prospective follow-up. All cancers detected
prior to, at or within 1 year after the age at the first
planned and performed colonoscopy were scored as
prior or prevalent cancers, and were excluded from the
analysis when scoring prospectively observed cancers.
Rectal cancer was not included because of known time-
trends in outcome related to changes in management
during the observation period and the low numbers of
cases.
The following information was used in the statistical
analyses: sex, path_MMR variant, age at inclusion, age at
last update, age at death, age at colon cancer, type of
cancer as indicated by the first three positions in the
International Classification of Diseases version 9 (ICD-9)
diagnostic system, the American Joint Committee on
Cancer (AJCC) stage of colon cancer (I–IV) and the time
since the last colonoscopy preceding the diagnosis of
colon cancer. We considered AJCC stage III-IV as ad-
vanced [2].
The time elapsed since the colonoscopy before the one
at which the cancer diagnosis was made was recorded and
categorized, as previously reported [2]. Longer or shorter
intervals between colonoscopies than planned may occur
for several reasons in the clinical setting, and so we re-
corded actual time since last colonoscopy. We did not
measure compliance with preset protocols, which would
have been complex since protocols had changed during
the observation period and different centres used different
protocols at different times. We also compared time inter-
vals and AJCC stage by MMR gene affected. Statistical
testing was performed by SYSTAT13©.
Survival analysis
Survival after colon cancer was estimated as previously
described [6, 7, 9]. Briefly, the Kaplan-Meier survival
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function from first prospectively detected colon cancer
diagnosis to death was calculated. To minimize probabil-
ities of death from other causes, survival calculations
were restricted to cases diagnosed with colon cancer at
65 years of age or younger.
Results
Ten centres in nine different countries (Finland,
Sweden, Norway, Denmark, The Netherlands, UK,
Spain, Israel and Australia) contributed to this study.
Together, they reported 196 path_MMR carriers with-
out prior or prevalent colon cancer at inclusion having
had prospectively detected colon cancer. Ten of these
had had two prospectively detected colon cancers and
were excluded, leaving 186 cases with one prospect-
ively detected colon cancer for survival analysis.
Among these, 96 path_MMR carriers having had no
prior or prevalent cancer in any organ were later pro-
spectively diagnosed with colon cancer at age 65 years
or younger. These 96 path_MMR carriers were se-
lected for survival analysis and included 77 path_
MLH1, 17 path_MSH2 and 2 path_MSH6 carriers.
The numbers of colon cancers detected within < 1.5,
1.5 to 2.5, 2.5 to 3.5 and > 3.5 years since previous colon-
oscopy were 9, 43, 31 and 13, respectively. The median
time since previous colonoscopy to colon cancer was 28
months (2.3 years). Only one patient was diagnosed with
a stage IV disease (path_MLH1 carrier with a 2.5 to 3.5
years interval, who died within 5 years of diagnosis). Ten
path_MLH1 carriers, 7 path_MSH2 carriers, and none of
the path_MSH6 carriers were diagnosed with a stage III
colon cancer (Table 1). Data on gender and colonoscopy
interval broken down by gene are presented in Table 2.
Five- and 10-year crude survival after colon cancers
that were diagnosed before 65 years of age in path_
MLH1, path_MSH2 and path_MSH6 carriers are pre-
sented in Table 3 and Fig. 1. Median follow-up time
after prospectively detected colon cancer was 14 years.
Ten-year survival when the last colonoscopy had been
undertaken < 1.5, 1.5–2.5, 2.5–3.5 or > 3.5 years before
diagnosis, was 89, 90, 90 and 92%, respectively (p = 0.91).
Ten year crude survival was 93% for stage I, 94% for
stage II and 82% for stage III (p < 0.001). There were no
significant differences in survival according to which
MMR gene was involved (p = 0.90).
We also performed a sensitivity analysis determining
survival according to the time since last colonoscopy by
including path_MMR carriers with all prospectively de-
tected colon cancers (i.e. also including those patients
with prior or prevalent cancer in other organs, of whom
143 had colon cancer diagnosed at 65 years of age or
younger), and arrived at similar results to those for the
96 path_MMR carriers without any prior or prevalent
cancer (Fig. 2) i.e. no significant association with time
since last colonoscopy (p = 0.93); and significant associ-
ation with stage (p < 0.001).
Discussion
In the current study, we found no demonstrable differ-
ence in crude survival after colon cancer in path_MMR
carriers who had had their last colonoscopy 3 years be-
fore the diagnosis of colon cancer, compared to those
with shorter times between last colonoscopy and diag-
nosed colon cancer. Considered together with our previ-
ous reports, in which we found no decrease in the
Table 1 Number of cases by gene and stage
CRC Stage path_MLH1 path_MSH2 path_MSH6
Stage I 37 7 1
Stage II 29 3 1
Stage III 10 7 0
Stage IV 1 0 0
Table 2 Gender and colonoscopy interval distribution by
path_MMR gene of the 96 path_MMR carriers included in the
study
Parameter path_MLH1 path_MSH2 path_MSH6
Gender
Female 41 9 2
Male 36 8 0
Colonoscopy interval
Less than 1.5 years 7 2 0
1.5 to 2.5 years 32 10 1
2.5 to 3.5 years 29 1 1
Over 3.5 years 9 4 0
Table 3 Crude survival (%) after selected colon cancer
diagnosed after initiation of colonoscopy surveillance and
before age of 65 years for path_MLH1, path_MSH2 and
path_MSH6 carriers with no cancer in any organ prior to, at, or
within 1 year of their first colonoscopy
Parameter 5-year
survival (%)
95% CI (%) 10-year
survival (%)
95% CI (%)
Interval
Less than 1.5 years 89 [43–98] 89 [43–98]
1.5 to 2.5 years 95 [83–99] 90 [75–96]
2.5 to 3.5 years 94 [77–98] 90 [72–97]
Over 3.5 years 92 [57–99] 92 [57–99]
Stagea
I 98 [84–99.7] 93 [79–98]
II 97 [80–99.6] 94 [78–98]
III 82 [55–94] 82 [55–94]
aIV: One path_MLH1 carrier who died before 5 years
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incidence of CRC with advanced stages of CRCs where
the interval since last colonoscopy was less than 3 years
before cancer diagnosis, our findings may be considered
to be in conflict with the view underlying the current
recommendations on the follow up of path_MMR car-
riers with colonoscopy more often than every 3 years.
In a previous report, we discussed the possibility that
not only microsatellite unstable non-invasive lesions,
but also infiltrating cancers in LS, may be removed by
the host immune system [2]. Aysel Ahadova et al. sug-
gested that although some CRCs in LS may develop
from MMR-proficient adenomas after secondary inacti-
vation of the MMR system, a larger portion of LS CRCs
appear to develop from MMR deficient crypt foci,
either through an adenomatous phase or as non-polyp
lesions with immediate invasive growth that may not
have colonoscopically visible precursor lesions [11, 12].
Our current report does not aim to provide a full dis-
cussion of the biological models that may explain our
results: the few we mention are provided to illustrate
the wide range of possible explanations that require
further investigation.
Our study included only path_MLH1 and path_MSH2
carriers, except for two path_MSH6 carriers, and any
conclusions based on this report should be applied to
path_MLH1 and path_MSH2 carriers only. Besides, it
has already been described that path_PMS2 carriers have
almost no incident cancer risk under surveillance.
Clinical guidelines should be based on observed
outcomes of interventions. Whatever the reasons for the
results presented herein, we report our observed pro-
spective empirical outcomes of clinical guidelines that
Fig. 1 Survival after colon cancer in 96 path_MMR carriers under 65 years of age without prior or prevalent cancer in any other organ
Fig. 2 Survival after colon cancer in 143 path_MMR carriers under 65 years of age with or without prior or prevalent cancer in any other organ
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aim to prevent colon cancer in path_MMR carriers. Our
data may therefore be useful in formulating future revi-
sions to clinical guidelines for LS.
In our study, the survival analyses included only colon
and not rectal cancers. There were several reasons for
this, including differences in the treatment, classification
and time from diagnosis to surgical resection of rectal
cancers (e.g. this can vary from immediate to delays of
several months due to neoadjuvant therapy). In addition,
wide variation in the treatment choices across different
regions/countries have been described [13]. Since these
differences may be confounders to our chosen endpoint,
survival by stage, we decided to perform survival analysis
only in colon cancers. It is, however, of utmost import-
ance to also report these measures for rectal cancer sep-
arately. To achieve this, we will need to collate data for
more rectal cancer cases than are currently reported to
the PLSD.
There are several limitations to the current study.
Numbers included are limited. All centres previously
having contributed to the PLSD reports were invited
to participate, but not all provided data to this report.
We present no information on survival after a second
colon cancer subsequent to a first colon cancer. It is
possible that some existing lesions were missed during
earlier colonoscopies that preceded the diagnosis of
colon cancers. We have not excluded that colonoscopy
with new techniques and better knowledge on what to
look for may prevent cancer and improve survival, but
even if so it still remains to be demonstrated that such
is possible to implement in a broader health care set-
ting: what we report is the observed outcome of health
care so far, not what putatively might have been ob-
tained otherwise. However, if colonoscopy quality did
play a significant role related to survival, the impact
might be expected to be greatest for the lesions missed
with a three-yearly strategy, and survival would be
expected to be worse in that group. Because we have
recently shown that there is no significant difference
between AJCC stages of cancers diagnosed when
colonoscopies are done yearly or three-yearly, and as
annual colonoscopy has been implemented more
recently, there is no reason to assume that colonos-
copies with short intervals were of lower quality. We
restricted our analysis to the core subset of 96 carriers
described to provide a robust crude survival analysis
for colon cancer in path_MMR carriers with as few
confounders as possible, and we found the same re-
sults when also including cases with prior or prevalent
cancers in other organs.
While we report the largest prospective analysis under-
taken so far of colon cancer survival in LS patients accord-
ing to time since last colonoscopy, we do not, based on the
current and our previous reports, advocate any revision of
current clinical guidelines, and the PLSD will ask more con-
tributors to provide data to repeat this study in an inde-
pendent data set. More detailed studies are needed to
understand why there are still some carriers dying from
colon cancer, and how this may be prevented. Health eco-
nomic studies are indicated to establish whether colonos-
copy more frequently than every 3 years is justified from a
resource perspective. These studies require data on the
costs from all aspects, including unwanted (side-) effects,
borne by health care systems and patients. The PLSD is
presenting some of the many pieces of evidence that need
consideration in discussions to revise current clinical guide-
lines for LS surveillance.
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